Proreo Pharma

Proreo Pharma is a German biotechnology company focused on the development of innovative therapies for thrombo-inflammatory diseases. The company's primary focus is on targeting Coagulation factor XIIa (FXIIa) to provide effective anticoagulation without the inherent bleeding risks associated with current standard-of-care treatments. Its lead candidate, PR-001, is a highly selective small molecule inhibitor designed to treat conditions such as thrombosis and stroke. By decoupling the processes of pathological clotting and physiological hemostasis, Proreo Pharma aims to transform the safety profile of cardiovascular interventions. The company leverages deep expertise in protease biology to address significant unmet needs in the cardiovascular space.